ATE435023T1 - Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen - Google Patents

Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen

Info

Publication number
ATE435023T1
ATE435023T1 AT97939108T AT97939108T ATE435023T1 AT E435023 T1 ATE435023 T1 AT E435023T1 AT 97939108 T AT97939108 T AT 97939108T AT 97939108 T AT97939108 T AT 97939108T AT E435023 T1 ATE435023 T1 AT E435023T1
Authority
AT
Austria
Prior art keywords
neoplasms
prophylaxis
therapy
formulations containing
therapeutic formulations
Prior art date
Application number
AT97939108T
Other languages
English (en)
Inventor
Elizabeth Shanahan-Prendergast
Original Assignee
Elizabeth Shanahan-Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elizabeth Shanahan-Prendergast filed Critical Elizabeth Shanahan-Prendergast
Application granted granted Critical
Publication of ATE435023T1 publication Critical patent/ATE435023T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004—Phospholipase A2 (3.1.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04011—Phosphoinositide phospholipase C (3.1.4.11)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
AT97939108T 1996-09-11 1997-09-10 Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen ATE435023T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2517996P 1996-09-11 1996-09-11
PCT/IB1997/001091 WO1998010776A1 (en) 1996-09-11 1997-09-10 Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms

Publications (1)

Publication Number Publication Date
ATE435023T1 true ATE435023T1 (de) 2009-07-15

Family

ID=21824505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97939108T ATE435023T1 (de) 1996-09-11 1997-09-10 Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen

Country Status (10)

Country Link
US (5) US20030175277A1 (de)
EP (1) EP1019068B1 (de)
AT (1) ATE435023T1 (de)
AU (1) AU741943B2 (de)
CA (1) CA2265631A1 (de)
DE (1) DE69739482D1 (de)
ES (1) ES2329529T3 (de)
HK (1) HK1028545A1 (de)
PT (1) PT1019068E (de)
WO (1) WO1998010776A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321089A (zh) 1998-09-08 2001-11-07 比奥莫勒克拉制品公司 增加肠吸收脂肪的方法和组合物
AU1534900A (en) * 1998-11-12 2000-06-05 Analytica Ltd A method of treatment
ES2282256T3 (es) * 2000-05-26 2007-10-16 Symphogen A/S Anticuerpos policlonales recombinantes o purificados para tratar la alergia.
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
DE60125420T2 (de) 2000-10-10 2007-09-27 University Of North Carolina At Chapel Hill Zusammensetzungen enthaltend phospholipase c inhibitoren und verfahren zur erhöhung parazellulärer permeabilität der epithelbarriere und endothelbarriere
EP1391207A1 (de) * 2001-04-24 2004-02-25 Luis Alberto Costa Verwendung einer phospholipase a2 zur herstellung von pharmazeutischen und/oder kosmetischen zusammensetzungen zur topischen und/oder systemischen behandlung und/oder prävention von krankheiten und/oder prozessen, die durch intra- und extrazelluläre erreger ausgelöst werden, die membran-phospholipide exprimieren
DE10330712A1 (de) * 2003-07-08 2005-01-27 Toximed Gmbh Pharmarzeutischer Wirkstoff gegen Kolonkarzinome und andere Tumorarten
DE10342747A1 (de) * 2003-09-16 2005-04-28 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Melanome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189471A (en) 1978-07-11 1980-02-19 Merck & Co., Inc. Immunologic glycolipid adjuvants
EP0064366A1 (de) 1981-04-29 1982-11-10 Beecham Group Plc Pharmazeutische Zusammensetzungen
EP0246861B1 (de) * 1986-05-19 1993-03-17 Ventech Research, Inc. Verwendung von Zusammensetzungen auf Basis von Crotoxin, zur Herstellung von Medikamenten zur Behandlung von Carcinomen
US5053492A (en) * 1986-08-07 1991-10-01 Board Of Regents, The University Of Texas System Immunopurification using monoclonal antibodies to Mojave toxin
US5164196A (en) * 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
US4822608A (en) * 1987-09-14 1989-04-18 Vespa Laboratories, Inc. Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom or proteinaceous or polypeptide components thereof
FR2623508B1 (fr) * 1987-11-20 1990-04-20 Commissariat Energie Atomique Proteine basique denommee phospholipase a2 isolee de venin de serpent de la famille des elapides et sa sequence en amino-acides, derives et fragments de ladite proteine, leur procede d'obtention, compositions therapeutiques et agents de diagnostic contenant ladite proteine et/ou ses derives et/ou ses fragments
US5622832A (en) * 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
JP2984029B2 (ja) * 1990-05-30 1999-11-29 塩野義製薬株式会社 膜型ホスホリパーゼａ▲下２▼を認識するモノクローナル抗体および膜型ホスホリパーゼａ▲下２▼の免疫測定法
US5178864A (en) * 1990-08-14 1993-01-12 Mit Lipoprotein removal by soluble enzymes
DE4142552A1 (de) 1991-12-21 1993-06-24 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen die typ i phospholipase a(pfeil abwaerts)2(pfeil abwaerts) als entzuendungshemmendes therapeutikum
US5565431A (en) * 1994-06-20 1996-10-15 Lipps; Binie V. Cancer cell inhibitors and method
FR2722692B1 (fr) 1994-07-20 1997-03-21 Rhone Poulenc Rorer Sa Medicament a base de phospholipase a2 de venin d'abeille
US5698583A (en) * 1994-11-15 1997-12-16 Crescenti; Ernesto J.V. Oligoelements and phospholipase A2 immuno-enhancer compositions, preparation thereof, and use thereof

Also Published As

Publication number Publication date
DE69739482D1 (de) 2009-08-13
US20120258115A1 (en) 2012-10-11
US20100196459A1 (en) 2010-08-05
CA2265631A1 (en) 1998-03-19
US8580744B2 (en) 2013-11-12
US20080044431A1 (en) 2008-02-21
AU741943B2 (en) 2001-12-13
ES2329529T3 (es) 2009-11-26
AU4132397A (en) 1998-04-02
EP1019068B1 (de) 2009-07-01
WO1998010776A1 (en) 1998-03-19
EP1019068A1 (de) 2000-07-19
US20030175277A1 (en) 2003-09-18
PT1019068E (pt) 2009-10-08
HK1028545A1 (en) 2001-02-23
US20040131632A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
PT758900E (pt) Toxina botulinica para a reducao da dor de cabeca devida a enxaqueca
DE3382458D1 (de) Haarwuchsmittel.
DK0880350T3 (da) Behandling af dissemineret sklerose
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
MX9401294A (es) Derivados de azolona sustituida
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE267583T1 (de) Arzneizubereitungen zur behandlung sexueller funktionsstörungen
ATE435023T1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
NO912435D0 (no) Farmasoeytiske preparater.
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
SE9601395D0 (sv) New therapeutic treatment 1
NO984446L (no) FremgangsmÕte for behandling av smerte
ES2095578T3 (es) Composicion para el tratamiento de mastitis y metritis.
BR0115215A (pt) Método para o tratamento de inflamações
ATE302011T1 (de) PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN
DE69218200D1 (de) Behandlung von leberkrebs
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
SE8306384L (sv) Farmaceutisk komposition
NO984198L (no) FremgangsmÕte for behandling av aggresjon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties